Aurinia Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview

Aurinia Pharmaceuticals

31/10/2023 18:55

* Aurinia Pharmaceuticals Inc  AUPH.OQ   AUPH.O  is expected
to show a fall in quarterly revenue when it reports  results 
    * The Victoria British Columbia-based  company is expected
to
report  a 31.0% decrease in revenue to $38.505 million from
$55.78 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aurinia
Pharmaceuticals
Inc is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $15​, above​ its last closing price
of $7.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.18       -0.18      -0.08     Beat    56.4
 Mar. 31 2023  -0.22       -0.22      -0.18     Beat    18.7
 Dec. 31 2022  -0.27       -0.27      -0.18     Beat    34​
 Sep. 30 2022  -0.17       -0.17      -0.06     Beat    64.4
 ​​Jun.        -0.22       -0.22      -0.25     Missed  -11.9
 30 2022                                                
 Mar. 31 2022  -0.27       -0.27      -0.27     Met     -1.1​
 Dec. 31 2021  -0.27       -0.27      -0.25     Beat    6.9
 Sep. 30 2021  -0.34       -0.33      -0.39     Missed  -17.2
 This summary was machine generated October 31 at 18:54 GMT.  All
figures in US dollars  unless otherwise stated